Lung Cancer; Lung cancer patients gain access to new treatment for 4th time in 2 months
Lung Cancer; Lung cancer patients gain access to new treatment for 4th time in 2 months
About this item
Full title
Lung Cancer; Lung cancer patients gain access to new treatment for 4th time in 2 months
Publisher
Atlanta: NewsRx
Journal title
Biotech Week, 2015, p.18
Language
English
Formats
Publication information
Publisher
Atlanta: NewsRx
Subjects
More information
Scope and Contents
Contents
Necitumumab binds to the epidermal growth factor receptor (EGFR), a protein commonly found on squamous NSCLC tumors, and blocks EGFR from binding its ligands, thus preventing tumor growth. Necitumumab is the first monoclonal antibody type of EGFR inhibitor to be approved in lung cancer, whereas there are a number of tyrosine kinase type of EGFR inh...
Alternative Titles
Full title
Lung Cancer; Lung cancer patients gain access to new treatment for 4th time in 2 months
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1747439071
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1747439071
Other Identifiers
ISSN
1535-2757
E-ISSN
1537-1395
How to access this item
Log in as a Library member
